ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

The ALVAC-HIV clade B/AE and equivalent SIV-based/gp120 + Alum vaccines successfully decreased the risk of virus acquisition in humans and macaques. Here, we tested the efficacy of HIV clade B/C ALVAC/gp120 vaccine candidates + MF59 or different doses of Aluminum hydroxide (Alum) against SHIV-Cs of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS Pathog
Autors principals: Schifanella, Luca, Barnett, Susan W., Bissa, Massimiliano, Galli, Veronica, Doster, Melvin N., Vaccari, Monica, Tomaras, Georgia D., Shen, Xiaoying, Phogat, Sanjay, Pal, Ranajit, Montefiori, David C., LaBranche, Celia C., Rao, Mangala, Trinh, Hung V., Washington-Parks, Robyn, Liyanage, Namal P. M., Brown, Dallas R., Liang, Frank, Loré, Karin, Venzon, David J., Magnanelli, William, Metrinko, Michelle, Kramer, Josh, Breed, Matthew, Alter, Galit, Ruprecht, Ruth M., Franchini, Genoveffa
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6890176/
https://ncbi.nlm.nih.gov/pubmed/31794588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.ppat.1008121
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars